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Abstract 
 
Objective. Disease-inducible promoters for the treatment of rheumatoid arthritis (RA) have 
the potential to provide regulated expression of therapeutic proteins in arthritic joints. In this 
study, we set out to identify promoters of human genes that are upregulated during RA and 
are suitable to drive the expression of relevant amounts of anti-inflammatory Interleukin-10 
(IL-10).  
Methods. Microarrays on RA joint tissues was compared to healthy controls. The CXCL10 
promoter was obtained from human cDNA and cloned into a lentiviral vector containing 
firefly luciferase. The promoter inducibility was determined in primary synovial cells and in 
THP1 cells. The luciferase gene was replaced with IL-10 to determine the therapeutic 
properties of the CXCL10p-IL10 lentiviral vector. 
Results. Microarray analysis yielded a list of 22 genes upregulated during RA. Of these 
genes, CXCL10 showed the highest induction in LPS-stimulated synovial cells. The promoter 
activation was strongest at 8-12h after stimulation with the pro-inflammatory cytokine TNFα 
and was re-inducible after 96h. The CXCL10 promoter showed a significant response to RA 
patient serum, compared to serum from healthy individuals. Primary synovial cells transduced 
with CXCL10p-IL10 showed a great increase in IL-10 production after stimulation, which 
reduced the release of pro-inflammatory cytokines TNFα and IL-1β. 
Conclusion. The selected proximal promoter of the CXCL10 gene responds to inflammatory 
mediators present in serum of RA patients and transduction by the lentiviral CXCL10p-IL10 
vector reduces inflammatory cytokine production by primary synovial cells from RA patients. 
CXCL10 promoter-regulated IL-10 overexpression can thus provide disease-inducible local 
gene therapy suitable for RA. 
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Gene therapy for rheumatoid arthritis (RA) enables transduced joint cells to express biological 
drugs. Because the therapy can be applied locally and requires fewer injections, the side 
effects of continuous systemic drug administration can be reduced. In addition, off-target 
effects can be even further reduced by using a disease-responsive promoter that is only active 
during disease flares and silent during remission.
1
 
 
Derivatives of currently applied biological drugs have been tested as a potential gene therapy 
in multiple clinical studies after successful application in animal models of RA, including the 
Interleukin-1 receptor antagonist (IL1-RA) and the soluble extracellular domain of the TNF 
receptor fused to an IgG tail.
2,3
 No severe adverse side effects were reported that could be 
contributed to the gene therapies.
4
 However, only minor clinical improvements were 
observed. These results solicit for the use of a more potent anti-inflammatory transgene, like 
Interleukin-10 (IL-10). IL-10 has pleiotropic effects and can inhibit the development of Th1 
cells and the production of multiple pro-inflammatory cytokines as comprehensively reviewed 
by Bijjiga and Martino.
5
  
 
Clinical studies with recombinant IL-10 are impeded by the short half-life of IL-10 in vivo.
6
 
In addition, Crohn’s disease patients systemically treated with high doses of recombinant IL-
10 showed a significant reduction in hemoglobin levels.
7
 These issues might be circumvented 
in RA by using local gene therapy. Recent studies have successfully attempted to provide 
disease-inducible expression of IL-10 in murine experimental arthritis.
8,9
 The promoters that 
were tested for therapeutic application with IL-10 in these studies were the IL1E-IL6P, a 
combination of the IL-1β enhancer element and the IL-6 promoter, the Saa3 promoter and the 
Mmp13 promoter. 
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The translation of the use of inducible promoters from experimental arthritis to the human 
situation is hampered by both differences in the disease process and the subsequent activation 
of the associated genes, as well as the differences in the sequences of homologous promoters. 
For instance, the Saa3 promoter showed the highest inducibility in previous studies,
10
 but is 
only present as a pseudogene in humans. 
 
In this study, we show the upregulation of the human CXCL10 promoter in joint tissue of RA 
patients and the inducibility of the isolated CXCL10 promoter in THP-1 monocytes and in 
primary synovial cells. When the CXCL10 promoter was used to drive the transcription of the 
IL-10 transgene in a lentiviral vector, IL-10 production was significantly increased in cells 
stimulated with pro-inflammatory cytokines. The increased production of IL-10 resulted in a 
decreased release of pro-inflammatory cytokines by synovial cells, indicating the potential of 
the CXCL10p-IL10 construct to provide a disease-regulated production of anti-inflammatory 
IL-10. 
 
Materials and methods 
Patient material 
Synovial samples for microarrays were obtained during surgery or by fine-needle arthroscopy 
and stored in liquid nitrogen until further processing. In total, an additional 8 synovial 
biopsies for digestion were obtained during surgery from the Department of Orthopedics 
(Radboud University Medical Center, Nijmegen, The Netherlands) or the Sint 
Maartenskliniek, Nijmegen, The Netherlands. Synovial biopsies were transported in DMEM 
culture medium, supplemented with 1% penicillin/streptomycin at 4°C. First, the pieces were 
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confirmed to contain a synovial lining by histological analysis of cryosections. Examples of 
the sample cryosections are shown in Figure S1.  
Subsequently, the pieces were digested with 50 µg/ml Liberase TM (Roche, Basel, 
Switzerland) for 1h at 37°C in plain RPMI culture medium. The digestion was quenched by 
adding 10% fetal calf serum (FCS). Subsequently, the synovial cells were passed through a 70 
µm cell strainer (Corning, NY, USA) and centrifuged for 5 min at 1500 rpm. Red blood cells 
were lyzed using RBC lysis buffer (155 nM NH4Cl, 12 mM KHCO3, 0.1 mM EDTA, pH 7.3) 
for 2 min at RT.  
Sera from RA patients were obtained from early RA at the Department of Rheumatic 
Diseases, Radboud University Medical Center, Nijmegen, Netherlands. Sera from age- and 
sex matched healthy controls were obtained from the Sanquin Bloedbank, Nijmegen, The 
Netherlands. Serum samples were stored at -80°C. All patients included in this study gave 
their informed consent and the study protocol was approved by the Medical Ethics 
Committee. In total, material of 28 patients was included in this study. 
 
Microarray analysis 
Total RNA was isolated from the synovial samples using the RNeasy kit for fibrous tissues 
(Qiagen, Venlo, Netherlands). 100 ng of total RNA was used for the preparation of 
biotinylated cRNA as described earlier
11
 and hybridized to a U133Plus 2.0 oligonucleotide 
array (Affymetrix, Santa Clara, CA, USA), according to the Affymetrix Expression Analysis 
Technical Manual for two-cycle amplification. The arrays were scanned using the GeneChip 
Scanner (Affymetrix) and analyzed using the GeneChip Operating Software version 1.4 
(Affymetrix). Array normalization and expression value calculations were performed by the 
DNA-Chip analyzer version 1.3 (www.dchip.org) using the Invariant Set normalization and 
the Model-based method.
12
 The RA synovium samples were obtained from the GEO database 
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(
13
, accession number GSE9027). The control samples were deposited under accession 
number …) 
 
Cell culture 
THP-1 monocytes were seeded in a 24-well plate at 3x10E5 cells/well for RNA analysis and 
multiplex assay or in a µClear white 96-well plate (Greiner Bio-one, Alphen a/d Rijn, 
Netherlands) at 5x10E4 cells/well for luciferase measurements in RPMI culture medium, 
supplemented with 10% FCS, 1 mM pyruvate and 1% pen/strep. Synovial cells were 
centrifuged and resuspended after red blood cell lysis and cultured at similar concentrations 
and conditions. All cell cultures were kept in humidified atmosphere at 37°C and 5% CO2. 
The cells were stimulated with E. Coli lipopolysaccharide (LPS) (Invivogen, San Diego, CA, 
USA), Pam3CSK4 (Invivogen), rhIL-1β (R&D systems, Oxford, UK), rhTNFα (Abcam, 
Cambridge, UK) or rhIL-10 (Life Technologies Europe, Bleiswijk, Netherlands) at 
concentrations indicated in the text. 
 
RNA isolation and qPCR 
Total RNA from cells was isolated using TRI Reagent (Sigma, St. Louis, MO, USA) 
according to the manufacturer’s recommendations and treated with DNase I (Invitrogen, 
Carlsbad, CA, USA) for 15 min. cDNA was synthesized by reverse transcription PCR using 
MLV Reverse transcriptase (Invitrogen) and oligo(dT) primers. The qPCR was performed 
using Power SYBR Green PCR master mix (Apllied Biosystems, Waltham, MA, USA) and 
the StepOnePlus Real-Time PCR system (Applied Biosystems) according to the 
manufacturer’s instructions. The reaction volume contained 5 µl SYBR master mix, 1 µl 2 
µM forward primer, 1 µl 2 µM reverse primer and 3 µl cDNA template. Primer sequences are 
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listed in Table S1. The PCR protocol consisted of 10 min at 95°C, followed by 40 cycles of 
15 seconds at 95°C and 60 seconds at 60°C. 
 
Plasmid cloning 
For the production of lentiviral vectors, we made use of the third generation self-inactivating 
lentiviral (sin) vector. Cloning of the pRLL-cPPT-PGK-luc-PRE-SIN vector has been 
described previously.
14
 The 535 bp proximal promoter of the CXCL10 gene was isolated from 
purified human genomic DNA (Promega, Madison, WI, USA) using Phusion polymerase 
(New England Biolabs, Ipswich, MA, USA), the forward primer 
TTTTGTCGACTCAAGGAGGACTGTCCAGGT and reverse primer 
TTTTGCTAGCGGTGCTGAGACTGGAGGTTC. The primers introduced restriction sites 
for SalI and NheI respectively. The promoter was first cloned into PCR-Script using the PCR-
Script CAM cloning kit (Agilent, Santa Clara, CA, USA) according to the manufacturer’s 
protocol. SalI and NheI (New England Biolabs) were used to clone the CXCL10 promoter in 
the pRRL-cPPT-mcs-luc-PRE-SIN vector. The human IL-10 transgene was isolated from 
cDNA obtained from primary human macrophages by nested PCR using forward primer 
AAAGAAGGCATGCACAGCTCA and reverse primer TGGAAGCTTCTGTTGGCTCC to 
obtain a 903 bp PCR nest. The 537 bp gene was subsequently isolated from the nest with 
forward primer GCTAGCGCCACCATGCACAGCTCAGCACTGCTC and reverse primer 
TCTAGATCAGTTTCGTATCTTCATTGTCATG, which introduced restriction sites for 
NheI and XbaI. NheI and XbaI (New England Biolabs) were used to replace the firefly 
luciferase gene in the pRLL-cPPT-CXCL10-luc-PRE-SIN by the therapeutic IL-10 gene.  
 
Lentivirus production 
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293T cells were seeded at density 1x10E5 cells/cm
2
 in a T75 culture flask in DMEM medium, 
supplemented with 10% FCS, 1 mM pyruvate, 1% pen/strep and 0.01 mM cholesterol 
(Sigma) one day prior to the plasmid transfection. The cells were co-transfected with a 
calcium phosphate precipitate containing 5,3 µg sin vector, 4,0 µg MDL packaging plasmid, 
3,5 µg VSV-G expression plasmid and 1,8 µg RSV-REV expression plasmid in 
mediumwithout antibiotics. After 16h, the medium was replaced and new complete medium 
containing the produced virus was collected after 24h and 48h. The supernatant was passed 
through a 0.22 µm Stericup filter (Millipore, Bedford, MA, USA). Subsequently, 32 ml 
supernatant was layered on 4 ml 20% sucrose (Sigma) and centrifuged for 2h at 25k rpm in a 
Surespin 6x50ml swingout bucket rotor (Sorvall) in a Discovery 100WX ultra centrifuge 
(Sorvall). The viral vectors were resuspended in sterile PBS and stored at -80°C. Virus 
concentrations were determined using the INNOTEST HIV antigen mAb kit (Diasorin, 
Saluggia, Italy) and expressed as ng p24/µl. Viral transduction of cells was performed with 50 
ng virus/5x10E4 cells in complete medium supplemented with 8 µg/ml polybrene (Sigma). 
 
Luciferase measurements 
The luciferase measurements were performed in 96-well white clear-bottom plates (Greiner 
Bio-one) in total volumes of 50-60 µl using the BrightGlo luciferase assay system (Promega). 
30 µl BrightGlo substrate was added to cells and light production was measured on a 
Lumistar luminometer (BMG, Offenburg, Germany). The values were corrected for the 
background signal and depicted as relative light units (RLU). 
 
Multiplex Elisa assay 
Cytokine and chemokine concentrations were determined by luminex multianalyte technology 
on the Bio-Plex 200 (Bio-Rad, Hercules, CA, USA) in combination with Bio-Plex pro human 
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cytokine kits (Bio-Rad) according to the manufacturer’s protocol. For IL-10, MCP-1, IL-6 
and IL-8 measurements, the culture supernatants were first diluted 25x. Samples below the 
detection limit were set at the lowest measureable quantity to perform statistical analysis. 
 
Statistical analysis 
Statistical analysis was performed using the Student’s t-test, 1-way ANOVA and 2-way 
ANOVA. Results are depicted as mean +/- SD and P-values < 0.05 were regarded as 
significant. 
 
Results 
Microarray analysis of RA synovium samples 
Potential disease-regulated promoters can be obtained from endogenous promoters of genes 
upregulated during disease. Therefore, we analyzed 20 microarrays of RA patient synovium 
biopsies and compared the gene expression levels to 8 control synovium biopsies without 
arthritis. The criteria for candidate genes included at least 10-fold upregulation in RA with 
P<0.01 compared to control and a minimal average relative probe intensity of 500 (arbitrary 
units) in RA to find promoters of sufficient capacity. The genes that do not code for a 
transcribed mRNA were removed from the list. In addition, the immunoglobulin genes were 
removed, as their proximal promoters rely on B-cell-specific factors and are dependent on 
intronic enhancer elements.
15
 22 genes met these criteria and are summarized in Table 1.  
 
The upregulation of the genes in the RA patient synovium was confirmed by qPCR on a 
subset of the biopsies (Supplemental Figure 2, Table 1). 
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We first determined if the gene upregulation in the joints was the result of pro-inflammatory 
signaling and if inflammation-sensitive cells can activate the gene promoters after stimulation 
in-vitro. Human synovial biopsies were digested and stimulated for 6h with bacterial 
lipopolysaccharide (LPS), which activates the pro-inflammatory TLR4 signaling. Several 
genes that were selected from the microarrays were upregulated after stimulation, of which 
CXCL10 showed the highest induction (Figure 1A). These results confirm that a pro-
inflammatory stimulus can activate transcription of the genes and the promoters of these 
genes therefore might be applicable for disease-regulated gene therapy. Similar results were 
obtained in human THP-1 monocytes after stimulation with the synthetic lipopeptide 
Pam3CSK4, which triggers TLR2 signaling
16
 (Figure 1B). Based on the microarray and the 
high inducibility in both synovial cells and THP1 cells, the CXCL10 promoter was selected 
for the remainder of this study. 
 
Promoter inducibility 
The proximal promoter of the CXCL10 gene was obtained from human cDNA and cloned into 
a lentiviral vector expressing the luciferase reporter gene. THP1 cells were transduced with 
the inducible reporter construct and stimulated with pro-inflammatory cytokines IL-1β, TNFα 
and TLR triggers LPS and Pam3CSK4 for 6h. The promoter showed a robust response to all 
stimuli (Figure 2A). In primary RA synovial cell culture, the isolated promoter was inducible 
by IL-1β, TNFα and LPS, but not by Pam3CSK4 (Figure 2B). 
An important characteristic of disease-inducible therapy for RA is the net response of the 
promoter to the balance of pro- and anti-inflammatory proteins present in the patient. 
Therefore, we compared the CXCL10 promoter response to serum from 63 RA patients to 
serum from 62 age- and sex matched healthy donors. The RA patient sera showed a stronger 
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induction of the CXCL10 promoter compared to healthy control sera (Figure 2C). This 
confirms that the inducible CXCL10 promoter is more active in RA patients.  
 
For the most accurate treatment of an RA patient, the inducible promoter activity should 
return to basal levels if the disease activity decreases and should be activated again if a new 
stimulus appears. Therefore, we compared the kinetics of the CXCL10 promoter to the 
constitutive active PGK promoter at different time points after stimulation with TNFα. 
Indeed, the PGK-luciferase activity remained around basal levels for 96 hours (Figure 2D). 
The CXCL10 promoter showed highest activity at 8-12h after the stimulation (Figure 2E), 
although the peak activity was still below PGK-level. As the TNFα was used and degraded by 
the cells,
17
 the promoter activity decreased. Re-stimulation of the cells with TNFα 8h prior to 
the 96h time point resulted in a significant second induction of the promoter. 
 
Recombinant human IL-10 effects on cytokine production 
The therapeutic potential for IL-10 was assessed using recombinant human IL-10 (rhIL-10). 
Primary RA synovial cell cultures of 3 patients were stimulated for 6h with LPS with or 
without the addition of rhIL-10. Despite differences in absolute quantity between patients, the 
production of TNFα was increased after LPS stimulation and could be significantly reduced 
with rhIL-10 (Figure 3A). To determine the effects of the cytokines produced by the synovial 
cells on the CXCL10 promoter, THP1 cells transduced with CXCL10prom-luciferase were 
stimulated with the synovial cell culture supernatant of one of the patients from Figure 4A 
(Figure 3B, closed bars). To test the effects of residual LPS and IL-10 that might be left in the 
supernatant from the synovial cells, LPS and rhIL-10 effects were first tested separately (open 
bars). No direct activation of the CXCL10 promoter by rhIL-10 was observed and LPS 
showed some activation of the CXCL10 promoter. However, the cell culture supernatant from 
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LPS-stimulated synovial cells showed a stronger induction compared to LPS alone. If the 
synovial cells were treated with rhIL-10, the capacity of its supernatant to activate the 
CXCL10 promoter was significantly reduced. This shows that activated synovial cells produce 
the required factors to activate the CXCL10 promoter and that IL-10 can diminish this 
production. All conditions were also tested in the presence of the specific TNFα-inhibitor 
Etanercept. In the presence of Etanercept, the CXCL10 promoter induction by synovial cell 
supernatant was significantly lower, indicating that TNFα produced by the stimulated 
synovial cell culture is the most important trigger for CXCL10 promoter activation in this 
setting. 
 
Effects of CXCL10-IL10 lentivirus on cytokine production 
The potential of the CXCL10 promoter to produce therapeutic quantities of IL-10 was tested 
by replacing the luciferase reporter transgene by the coding region of the human IL-10 gene 
(CXCL10p-IL10). THP-1 cells transduced with PGK-luciferase control lentiviral vector 
produced low quantities of IL-10 (Figure 4A). After transduction with CXCL10p-IL10, the 
basal activation of the of the CXCL10 promoter already resulted in increased IL-10 levels. 
Stimulation of the transduced cells with Pam3CSK4 caused a significant increase in 
production of IL-10. Pam3CSK4-stimulated THP-1 cells with control virus showed a marked 
increase in production of inflammatory cytokines MCP-1, IL-6 and IL-8 (Figure 4B-D). The 
release of these cytokines was inhibited by the CXCL10p-IL10 lentivirus, which shows the 
anti-inflammatory potential of the CXCL10p-IL10 treatment. 
 
Subsequently, the CXCL10p-IL10 lentivirus was tested in synovial cell cultures of three 
patient donors. After transduction with control virus or CXCL10p-IL10, the cells were 
stimulated with 5 or 100 ng/ml LPS. Only minor quantities of IL-10 were produced by cells 
with the control virus (Figure 5A). After transduction with the CXCL10p-IL10 lentivirus, 
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basal production levels of IL-10 were observed, which significantly increased after LPS 
stimulation in all patients, although the magnitude varied between patients. LPS triggered the 
release of TNFα, which was reduced by the CXCL10p-IL10 treatment of the cells (Figure 
5B). With the exception of the third donor, the same effects were also observed for IL-1β. In 
the third donor, IL-1β levels remained low after stimulation with LPS (Figure 5C). The 
production of MCP-1, IL-8 and IL-6 were also decreased in cells transduced with CXL10p-
IL10, although the decrease was not significant for most samples (Supplemental Figure 3). 
These results show that in the synovial cells of the patient, the CXCL10p-IL10 gene therapy 
can provide inducible expression of therapeutic levels of IL-10 that can suppress the 
production of pro-inflammatory cytokines. 
 
Discussion 
In this study we showed that the promoter from the CXCL10 gene is inducible by pro-
inflammatory TLR triggers and cytokines. In human THP-1 monocytes, the promoter showed 
a significant induction by RA patient serum, compared to healthy control serum. Using the 
CXCL10p-IL10 lentivirus in LPS-stimulated cells from RA patient biopsies, therapeutic 
levels of anti-inflammatory IL-10 were produced that could reduce the release of pro-
inflammatory cytokines TNFα, IL-1β, IL-6, IL-8 and MCP-1. 
The promoters of genes that were upregulated in RA synovium microarrays are the possible 
candidates for disease-regulated therapy. We first determined if the gene upregulation was the 
result of pro-inflammatory signaling rather than an altered cell composition in RA synovium 
by using broad TLR triggers which activate the major inflammatory transcription factors.
18
 
TLRs are important players in RA and can be triggered by damage-associated molecular 
patterns (DAMPs) present in the RA joint.
19
 A TLR2 trigger was used for THP1 cells, 
because TLR2 shows the highest expression in THP1 cell.
20
 In contrast, TLR2 is not 
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uniformly expressed on synovial fibroblasts and is upregulated after stimulation.
21,22
 
Therefore, the synovial cell cultures were stimulated with a TLR4 ligand. Based on the 
obtained data, the promoter of the CXCL10 gene was selected. In accordance with our results, 
previous studies have shown increased levels of CXCL10 in synovial fluid of RA patients.
23
 
CXCL10 is a C-X-C motif ligand chemokine, responsible for the recruitment of several 
immune cell types into the inflamed joint.
24
 The isolated region of the CXCL10 promoter 
contains predicted binding sites for immunoregulatory transcription factors C/EBPβ, NF-κB, 
AP-1 and an interferon-stimulated response element (ISRE).
25
 Point mutations in the NF-κB 
and the ISRE sites resulted in reduced promoter activity after stimulation with TNFα and 
IFNγ or by TLR triggers in hepatocytes.26 Interestingly, promoter constructs with mutations in 
the AP-1 or C/EBPβ binding sites showed increased activity upon stimulation, indicating 
orchestration of the promoter activity by multiple factors. 
The CXCL13 gene, also known as B-lymphocyte chemoattractant, showed the highest 
upregulation in the RA microarrays and in stimulated THP-1 cells. In mice, the promoter of 
CXCL13 contains a TATA-box and transcription factor binding sites.
27
 In humans this region 
is conserved, but located in a large intron in the 5’UTR. We isolated both the proximal 
promoter region from the human transcription start site and the first intron, but we could not 
observe an upregulation of either promoter activity after stimulation (data not shown). In 
addition, we did not find an upregulation of endogenous CXCL13 in Pam3CSK4-stimulated 
synovial cells. 
During RA pathogenesis, cells in the joint produce chemokines and cytokines to induce 
pannus formation and attract different immune cells to the joint, including neutrophils, 
monocytes, T-cells and B-cells.
28,29
 As a consequence, the synovial cell cultures after 
digestion of the synovium are of heterogeneous composition with patient-to-patient variation. 
This results in differences in cytokine production levels. For example, Il-1β has been 
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suggested to be predominantly produced by activated monocytes and macrophages.
30
 The 
third donor in Figure 5 showed the highest TNFα production upon stimulation, but only a very 
low production of IL-1β, which might reflect a low abundance of monocytes.  
In general, the cells in the synovium of RA patients have an inflammatory phenotype, which 
has also been observed in microarrays. Compared to healthy controls, the signaling networks 
associated with upregulated genes in RA include inflammatory response, T-cell activation and 
apoptosis.
31
 As a result, the cytokine concentrations are increased in the synovial fluid of RA 
patients.
32
 The inflammatory phenotype of the synovial cells in this study is reflected by the 
basal production of IL-1β (Figure 5C) and IL-10 after CXCL10p-IL10 transduction (Figure 
6A) and by a relatively high basal activity of the CXCL10 promoter in RA synovial cells 
(Figure 2B).  
To avoid effects of the basal activation state on the CXCL10 promoter, THP-1 cells were used 
to study promoter activation. THP-1 cells are human monocytes which are responsive to 
multiple TLR ligands and cytokines and can subsequently activate different inflammatory 
pathways.
33
 In addition, gene expression analysis of peripheral blood in RA patients showed 
an enrichment in monocyte-specific transcripts.
34
 indicating that THP-1 is a sensitive cell 
model, relevant to RA. Indeed, the CXCL10 promoter in THP-1 cells showed a strong 
induction by the cytokines produced by stimulated synovial cells. In addition, the 
responsiveness of the CXCL10 promoter in a monocyte cell line to RA serum factors might 
enable the use of the promoter to treat systemic components of the disease, like 
atherosclerosis and autoimmunity. 
Patients with inherited deficiencies in IL-10 signaling are rare, but suffer from early-onset 
inflammatory bowel disease (IBD).
35
 In addition, some studies found that the frequency of a 
polymorphism associated with low serum levels of IL-10 was increased in RA patients.
36,37
 
Currently, research is focusing on obtaining long-term active IL-10 targeted to the inflamed 
 Page 15 of 36 
H
um
an
 G
en
e 
Th
er
ap
y
D
ise
as
e-
re
gu
la
te
d 
ge
ne
 th
er
ap
y 
w
ith
 a
nt
i-i
nf
la
m
m
at
or
y 
in
te
rle
uk
in
-1
0 
un
de
r c
on
tro
l o
f t
he
 C
X
CL
10
 p
ro
m
ot
er
 fo
r t
he
 tr
ea
tm
en
t o
f R
he
um
at
oi
d 
A
rth
rit
is.
 (d
oi:
 10
.10
89
/hu
m.
20
15
.12
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
16 
16 
 
joint both by disease-responsive gene therapy and by fusing IL-10 to homing antibodies
38
 to 
provide regulated suppression of the inflammation. 
In conclusion, we have shown the temporal and spatial activation of the CXCL10 promoter, 
which was used to provide inducible expression of the anti-inflammatory IL-10. The vector 
was capable of reducing the release of pro-inflammatory cytokines by RA synovial cells and 
might therefore be suited to provide local and disease-responsive gene therapy in RA patients. 
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Figure 1: Upregulation of candidate genes in synovial cells and THP1 cells after TLR 
stimulation. A) Gene expression levels in primary cell cultures of digested synovial biopsies 
from patient 21after 6h stimulation with 100 ng/ml LPS. Genes are sorted from left to right 
according to fold induction over unstimulated cells. B) Gene expression levels in THP-1 cells 
stimulation with 100 ng/ml Pam3CSK4. Expression levels are depicted as threshold cycle 
(CT) +/- SD, corrected for GAPDH expression. Statistical analysis was performed by 
Student’s t-test. * =P<0.05, ** =P<0.01, *** =P<0.001. 
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Figure 2: Inducibility of the CXCL10 promoter in synovial cells and THP1 cells. A) Relative 
light signal of CXCL10 promoter-luciferase construct after stimulation with pro-inflammatory 
factors. THP1 cells were transduced with CXCL10 promoter-luciferase lentiviral vector and 
stimulated for 6h with 10 ng/ml IL-1β, 10 ng/ml TNFα, 100 ng/ml LPS or 100 ng/ml 
Pam3CSK4. Light values are shown as relative light units (RLU) +/- SD. B) CXCL10 
promoter-luciferase construct activation in primary RA synovial cell culture from patient 22. 
C) CXCL10 promoter-luciferase activation by RA patient serum. A stably transduced THP1 
clone was stimulated with 10% RA patient serum or age- and sex-matched healthy control 
serum (HC). The light signal after 6h is shown as RLU, corrected for the average signal from 
the control group +/- SD. D,E) THP-1 cells were transduced with lentiviral PGK-luciferase 
vector (D) or CXCL10-luciferase (E) and stimulated with 10 ng/ml TNFα. At multiple time 
points, the luciferase activity was determined. Light values are shown as relative light units 
(RLU) +/- SD. A second 10 ng/ml TNFα stimulation was provided at 88h, 8h prior to the last 
measurement. For statistical analysis, the re-stimulated sample was compared to the 96h time 
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point without re-stimulation.  Statistical analysis was performed by Student’s t-test compared 
to the medium control. * =P<0.05, ** =P<0.01, *** =P<0.001. 
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Figure 3: TNFα levels in the supernatant of stimulated synovial cells and the activation of the 
CXL10p-luciferase by the supernatant. A) Synovial biopsies from patient 23, 24 and 25 were 
digested using Liberase and passed through a cell strainer. After red blood cell lysis, cells 
were seeded and allowed to attach and recover. Subsequently, the synovial cell suspension 
was stimulated for 6h with 5 ng/ml LPS and 20 ng/ml recombinant human IL-10. The cell 
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culture medium was removed and the produced TNFα was measured using multiplex assay. 
B) THP1 cells stably transduced with the CXCL10p-luciferase reporter lentivirus were 
stimulated for 6h with medium containing 20 ng/ml recombinant IL-10 (+I10), 5 ng/ml LPS 
(+L5), 100 ng/ml LPS (+L100) or a combination (open bars). In addition, the cells were 
stimulated with the cell culture supernatant obtained from Figure 4A (closed bars) that might 
contain residual IL-10 (I10) or LPS (L(5) and L(100)). All samples were tested in the 
presence and absence of 50 ng/ml TNFα-inhibitor Etanercept. Light values are shown as 
relative light units (RLU) +/- SD. Results were similar with supernatants from all three 
patients (data not shown). Statistical analysis between subgroups of different stimulations was 
performed by 2-way ANOVA and other comparisons were performed by Student’s t-test. ** 
=P<0.01, *** =P<0.001. 
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Figure 4: Production and effects of IL-10 in CXCL10p-IL10 transduced THP1-cells. A) 
THP-1 cells were transduced with lentiviral vectors containing PGK-luciferase or CXCL10p-
IL10. After 48h, the cells were stimulated with medium control or with 100 ng/ml Pam3CSK4 
for 24h. IL-10 production was measured in the culture supernatant by multiplex assay. 
Statistical analysis was performed by 1-way ANOVA. B-D) THP-1 cell culture supernatant 
concentrations of MCP-1 (B), IL-6 (C) and IL-8 (D). Statistical analysis was performed by 
Student’s t-test, compared to the stimulated control cells. * =P<0.05, *** =P<0.001. 
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Figure 5: Production and effects of IL-10 on TNFα and IL-1β in CXCL10p-IL10 transduced 
synovial cells. Synovial tissue biopsies from patient 26, 27 and 28 were digested and cells 
were transduced with lentiviral PGK-luciferase (control) or lentiviral CXCL10p-IL10. After a 
minimum of 48h after transduction, the cells were stimulated for 24h with 5ng/ml LPS or 100 
ng/ml LPS. The supernatant was collected and the concentrations of IL-10 (A), TNFα (B) and 
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IL-1β (C) were measured by multiplex assay. The cytokine concentration of samples left of 
the dotted line are shown on the left y-axis and the samples on the right of the dotted line are 
depicted on the right y-axis. Statistical analysis was performed by 1-way ANOVA. * 
=P<0.05, ** =P<0.01, *** =P<0.001. 
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Supplemental Figure 1: Examples of histological sections of the synovium samples used in 
this study from patients 23, 24, 26 and 27. 7 µm cryosections were stained with haematoxylin 
and eosin.  
 
Supplemental Figure 2: Gene expression levels of genes upregulated in RA in synovium 
biopsies. n=4 and n=5 samples per group were measured and the expression levels are 
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depicted as threshold cycle (CT) +/-SD, corrected for GAPDH expression. Statistical analysis 
was performed by Student’s t-test. * =P<0.05, ** =P<0.01. 
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Supplemental Figure 3: Production and effects of IL-10 on MCP-1, IL-8 and IL-6 in 
CXCL10p-IL10 transduced synovial cells. Synovial tissue biopsies from patient 26, 27 and 28 
were digested and cells were transduced with lentiviral PGK-luciferase (control) or lentiviral 
CXCL10p-IL10. After a minimum of 48h after transduction, the cells were stimulated for 24h 
with 5ng/ml LPS or 100 ng/ml LPS. The supernatant was collected and the concentrations of 
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MCP-1 (A), IL-8 (B) and IL-6 (C) were measured by multiplex assay. Statistical analysis was 
performed by 1-way ANOVA. * =P<0.05, ** =P<0.01, *** =P<0.001. 
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Gene 
symbol 
description 
Average 
HC 
Average 
RA 
RA/HC P-value ΔΔCt 
SPP1 secreted phosphoprotein 1 
380,4 
(346,9) 
8773,6 
(6754,4) 
23,1 0,00001 8,0 
SLAMF8 SLAM family member 8 71,9 (29,3) 
889,9 
(741,1) 
12,4 0,00005 6,5 
RGS1 
regulator of G-protein 
signalling 1 
49,6 (63,0) 
598,0 
(495,8) 
12,0 0,00005 6,8 
CCL18 
chemokine (C-C motif) ligand 
18 
447,4 
(214,5) 
5279,3 
(4523,3) 
11,8 0,00007 7,8 
CXCL13 
chemokine (C-X-C motif) 
ligand 13 
10,2 (3,5) 
738,7 
(746,3) 
72,3 0,00017 12,0 
IL4I1 interleukin 4 induced 1 52,8 (12,6) 
677,3 
(664,2) 
12,8 0,00024 7,7 
VSNL1 visinin-like 1 18,6 (4,5) 
587,7 
(629,3) 
31,5 0,00035 2,3 
TREM1 
triggering receptor expressed 
on myeloid cells 1 
295,7 
(199,8) 
3185,4 
(3274,7) 
10,8 0,00044 6,6 
NMES1 
normal mucosa of 
esophagus specific 1 
39,3 (6,5) 
808,5 
(890,3) 
20,6 0,00052 9,0 
CXCL8 
chemokine (C-X-C motif) 
ligand 8 
126,5 
(131,5) 
1555,3 
(1742,5) 
12,3 0,00084 6,6 
CXCL10 
chemokine (C-X-C motif) 
ligand 10 
92,5 (93,8) 
1065,3 
(1270,8) 
11,5 0,00146 6,3 
CXCL9 
chemokine (C-X-C motif) 
ligand 9 
202,2 
(226,7) 
2058,4 
(2430,9) 
10,2 0,00151 ND 
MMP13 matrix metallopeptidase 13  41,2 (10,2) 
930,0 
(1192,5) 
22,6 0,00175 6,7 
CXCL6 
chemokine (C-X-C motif) 
ligand 6 
37,6 (21,9) 
600,2 
(778,8) 
15,9 0,00221 5,4 
CSN1S1 casein alpha s1 
336,5 
(626,5) 
5763,7 
(8196,4) 
17,1 0,00412 6,2 
FKBP11 
FK506 binding protein 11, 19 
kDa 
63,0 (30,7) 
732,6 
(1023,1) 
11,6 0,00434 6,5 
TNFRSF17 
tumor necrosis factor 
receptor superfamily, 
member 17 
26,8 (2,1) 
550,5 
(839,1) 
20,5 0,00582 ND 
SLAMF7 SLAM family member 7 36,7 (12,6) 
527,5 
(808,8) 
14,4 0,00689 8,7 
COL1A1 collagen, type I, alpha 1 45,2 (17,7) 
608,9 
(950,1) 
13,5 0,00786 4,1 
POU2AF1 
POU domain, class 2, 
associating factor 1 
50,7 (11,7) 
1473,9 
(2413,0) 
29,1 0,00811 9,8 
ADAMDEC1 ADAM-like, decysin 1 31,7 (27,8) 
576,7 
(924,8) 
18,2 0,00818 9,6 
IBSP Integrin-binding sialoprotein 25,0 (16,0) 
531,1 
(873,4) 
21,2 0,00897 4,7 
Table 1: List of genes upregulated in RA synovium, compared to control synovium 
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20 microarrays on RA synovium and 8 microarrays on control synovium. The average probe 
intensity was calculated with dchip using the invariant set normalization method and the 
model-based method. Depicted are the average intensity (+/- standard deviation) of the 
microarray sets, the index RA/HC, the P-value calculated by Student’s t-test and the ΔΔCt 
values of the control PCR of RA biopsies compared to healthy controls. HC = healty control; 
RA = rheumatoid arthritis. 
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Gene symbol Forward primer (5'→3') Reverse primer (5'→3') 
GAPDH ATCTTCTTTTGCGTCGCCAG TTCCCCATGGTGTCTGAGC 
CXCL13 CTCTGCTTCTCATGCTGCTG CAGCTTGAGGGTCCACACAC 
VSNL1 CCAATGGGGAGGCTAAATC GAAGTCAATGGTGCCGTC 
POU2AF1 CAATGTCACGACAAGAAGCT CACGGGAAATAGGTGAGGG 
SPP1 CTCCTAGGCATCACCTGTG GGGTATTTGTTGTAAAGCTGCT 
MMP13 ATTAAGGAGCATGGCGACTTCT CCCAGGAGGAAAAGCATGAG 
IBSP GCAGTAGTGACTCATCCGA CTCCTTCATTTGAAGTCTCCTC 
NMES1 AGGAAGGAACTCATTCCCT CCAAAGAGAATACACAGCGA 
TNFRSF17 CGACTCTGACCATTGCTTTCC AAGCAGCTGGCAGGCTCTT 
ADAMDEC1 TCAAACTCAAGCAATAGCCA TGTCTGGTTGTTCTTGATCTC 
CSN1S1 AGGCTCTGATAACCATGAGG GTTTCTCTGCCTGTTCATACC 
CXCL6 AGAGCTGCGTTGCACTTGTT GCAGTTTACCAATCGTTTTGGGG 
SLAMF7 TCCACTGTGGAAATACCGA GGCAAATAGCCTTGGTGTG 
COL1A1 AGATCGAGAACATCCGGAG AGTACTCTCCACTCTTCCAG 
IL4I1 CTCAAAGACCTCAAGGCAC CCCGAGAAGATATTCCAAGAG 
SLAMF8 CTCAAGGTGTACGATGCAG GTTATTTCGCTGATGTTGGG 
CXCL8 AGAAGTTTTTGAAGAGGGCTGAGA AGTTTCACTGGCATCTTCACTGATT 
RGS1 ACTCATTCACTTCTAGACGAC GGTATGCTTTCATATCCATTCC 
CCL18 GGTGTCATCCTCCTAACCA GTCGCTGATGTATTTCTGGAC 
FKBP11 GATTCCAGGTCTGGAGCAG CATAGGCCAAGTGAGAAGGA 
CXCL10 ATTTGCTGCCTTATCTTTCTG GACATCTCTTCTCACCCTTCT 
TREM1 TTGTCTCAGAACTCCGAGC CATTTCACATCCAGGGTCTG 
CXCL9 GGAGTGCAAGGAACCCCAGTA GAGAAACAGGTCAGCCAAAAG 
Table S1: List of primer sequences for qPCR analysis 
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Supplemental Figure 2: Gene expression levels of genes upregulated in RA in synovium biopsies. n=4 
and n=5 samples per group were measured and the expression levels are depicted as threshold cycle 
(CT) +/-SD, corrected for GAPDH expression. Statistical analysis was performed by Student’s t-test. * 
=P<0.05, ** =P<0.01. 
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